Glycerophosphorylethanolamine (sodium salt)
| Code | Size | Price |
|---|
| TAR-T37531-1mg | 1mg | £317.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Glycerophosphorylethanolamine is an active phosphodiester metabolite of phosphatidylethanolamine.1,2It promotes aggregation of amyloid-β (1-40) (Aβ40)in vitro, and levels of glycerophosphorylethanolamine are elevated in postmortem brains isolated from patients with Alzheimer?s disease.
CAS:
883288-78-6
Formula:
C5H13NO6P?Na
Molecular Weight:
237.1
Purity:
0.98
SMILES:
O=P(OCCN)(OCC(CO)O)[O-].[Na+]
References
Blusztajn, J.K., Lopez Gonzalez-Coviella, I., Logue, M., et al.Levels of phospholipid catabolic intermediates, glycerophosphocholine and glycerophosphoethanolamine, are elevated in brains of Alzheimer?s disease but not of Down?s syndrome patientsBrain Res.536(1-2)240-244(1990)
Klunk, W.E., Xu, C.J., McClure, R.J., et al.Aggregation of ?-amyloid peptide is promoted by membrane phospholipid metabolites elevated in Alzheimer?s disease brainJ. Neurochem.69(1)266-272(1997)